Literature DB >> 16351585

Oral acute toxicity of polyenylphosphatidylcholine (PPC) in rats.

Sanja Krosnjar1, Maida Todić, Sanela Bakić, Begler Begović, Irfan Zulić, Midhat Vehabović.   

Abstract

Endogen phospholipids play a major role in determining the structure and nature of cell membranes. A deficiency of phospholipids in cellular membranes makes it almost impossible for the cell membrane to perform its function as a selective barrier between what passes in and out of the cell. Polyenylphosphatidylcholine chemical structure corresponds to that of endogen phospholipids, but it possesses functional superiority because of its content of unsaturated fatty acids. Polyenylphosphatidylcholine integrates in the cell membrane and organelle systems while becoming their constitutive elements. A healthy cell membrane leads to healthy cells and then healthy tissue and then to healthy organs or body systems and finally, healthy bodies and minds. For a long time, polyenylphosphatidylcholine in combination with vitamins has been used in the treatment of numerous health problems such as liver diseases, dyslipoproteinaemias and different intoxications with consequent liver failure. The main aim of toxicology studies is evaluation of the toxic potential and risks of human exposition to the substance. According to the Organization for Economic Cooperation and Development (OECD) acute oral toxicity refers to those adverse effects occurring following oral administration of a single dose of a substance or multiple doses given within 24 hours. LD50 (median lethal dose), oral, is a statistically derived single dose of a substance that can be expected to cause death in 50 per cent of animals when administered by the oral route. Our acute toxicity study was performed on albino Wistar rats. Animals were randomised in three experimental and one control group, each of 5 males and 5 females. Study was based on the administration of a single oral dose of the test substance (polyenylphosphatidylcholine) to each experimental animal. There were three dose-levels of the test substance: 300, 500 and 1000 mg/kg. Test substance administration day was the first day of the observation period that lasted 14 days. Control animals were given milk vehicle. At the end of the study, no statistically significant differences between experimental and control animals were observed concerning the recorded parameters: body weight, respiratory rate, tremor, faeces and phonation quality, indicating the absence of the test substance acute toxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16351585      PMCID: PMC7202149          DOI: 10.17305/bjbms.2005.3273

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  10 in total

1.  Regulatory toxicology: objectives and tasks defined by the working group of the German society of experimental and clinical pharmacology and toxicology.

Authors:  H-P Gelbke
Journal:  Toxicol Lett       Date:  2002-02-07       Impact factor: 4.372

2.  Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression.

Authors:  X Ma; J Zhao; C S Lieber
Journal:  J Hepatol       Date:  1996-05       Impact factor: 25.083

3.  Dietary polyenylphosphatidylcholine decreases cholesterolemia in hypercholesterolemic rabbits: role of the hepato-biliary axis.

Authors:  E Polichetti; A Janisson; P L de la Porte; H Portugal; J Léonardi; A Luna; P La Droitte; F Chanussot
Journal:  Life Sci       Date:  2000-10-13       Impact factor: 5.037

4.  Alcohol-induced pancreatic oxidative stress: protection by phospholipid repletion.

Authors:  S I Aleynik; M A Leo; M K Aleynik; C S Lieber
Journal:  Free Radic Biol Med       Date:  1999-03       Impact factor: 7.376

Review 5.  Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis.

Authors:  Charles S Lieber
Journal:  Alcohol       Date:  2004-08       Impact factor: 2.405

Review 6.  New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments.

Authors:  Charles S Lieber
Journal:  Curr Gastroenterol Rep       Date:  2004-02

7.  Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group.

Authors:  C Niederau; G Strohmeyer; T Heintges; K Peter; E Göpfert
Journal:  Hepatogastroenterology       Date:  1998 May-Jun

8.  Cytoprotective effects of polyenoylphosphatidylcholine (PPC) on beta-cells during diabetic induction by streptozotocin.

Authors:  Seung-Hee Lee; Yu-Mi Han; Bon-Hong Min; In-Sun Park
Journal:  J Histochem Cytochem       Date:  2003-08       Impact factor: 2.479

9.  II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease.

Authors:  Charles S Lieber; David G Weiss; Roberto Groszmann; Fiorenzo Paronetto; Steven Schenker
Journal:  Alcohol Clin Exp Res       Date:  2003-11       Impact factor: 3.455

10.  Effects of polyenylphosphatidylcholine on cytokines, nitrite/nitrate levels, antioxidant activity and lipid peroxidation in rats with sepsis.

Authors:  Semra Demirbilek; Mehmet Ozcan Ersoy; Savaş Demirbilek; Abdurrahman Karaman; Melih Akin; Mehmet Bayraktar; Nihayet Bayraktar
Journal:  Intensive Care Med       Date:  2004-03-26       Impact factor: 17.440

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.